AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; and Bristol-Myers Squibb Company. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:ABBV
Previous Symbol
CUSIP00287Y10
Phone847-932-7900
Debt
Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.08
Price-To-Earnings
Trailing P/E Ratio16.34
Forward P/E Ratio11.54
P/E Growth0.85
Sales & Book Value
Annual Sales$28.22 billion
Price / Sales4.88
Cash Flow$6.5849 per share
Price / Cash13.90
Book Value($1.94) per share
Price / Book-47.18
Profitability
EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins23.50%
Return on Equity2,006.63%
Return on Assets17.63%
Miscellaneous
Employees29,000
Outstanding Shares1,504,220,000
Market Cap$137.68 billion
OptionableOptionable
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Monday, November 5th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $1.07 per share on Friday, February 15th. This represents a $4.28 dividend on an annualized basis and a dividend yield of 4.68%. The ex-dividend date of this dividend is Monday, January 14th. This is a boost from AbbVie's previous quarterly dividend of $0.96. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie announced that its board has approved a share buyback plan on Friday, February 16th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, November, 2nd. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.01 by $0.13. The firm earned $8.24 billion during the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a net margin of 23.50% and a return on equity of 2,006.63%. The firm's quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.41 EPS. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie issued an update on its FY18 earnings guidance on Friday, November, 2nd. The company provided earnings per share (EPS) guidance of $7.90-7.92 for the period, compared to the Thomson Reuters consensus estimate of $7.88.
What price target have analysts set for ABBV?
17 Wall Street analysts have issued 1 year price objectives for AbbVie's shares. Their forecasts range from $65.61 to $144.00. On average, they expect AbbVie's stock price to reach $101.9480 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for AbbVie.
What is the consensus analysts' recommendation for AbbVie?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug, Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret’s launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market. Moreover, AbbVie has an impressive late-stage pipeline with launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, potential biosimilar competition to Humira in Europe this year is an overhang." (10/1/2018)
- 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)
Has AbbVie been receiving favorable news coverage?
News articles about ABBV stock have been trending very positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
Are investors shorting AbbVie?
AbbVie saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 25,440,102 shares, a drop of 22.1% from the October 15th total of 32,649,937 shares. Based on an average daily volume of 6,795,353 shares, the short-interest ratio is presently 3.7 days. Approximately 1.7% of the company's shares are sold short. View AbbVie's Current Options Chain.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN) and Celgene (CELG).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
- Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
- Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 50)
- Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)
Who are AbbVie's major shareholders?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.71%), BlackRock Inc. (6.31%), Capital International Investors (1.83%), Capital World Investors (1.69%), Bank of New York Mellon Corp (1.05%) and FMR LLC (0.58%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Which major investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, Deutsche Bank AG, Renaissance Technologies LLC, TIAA CREF Investment Management LLC, Prudential Financial Inc., Alliancebernstein L.P. and Bahl & Gaynor Inc.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Which major investors are buying AbbVie stock?
ABBV stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Matthew Goff Investment Advisor LLC, FMR LLC, Robeco Institutional Asset Management B.V., AQR Capital Management LLC, Assenagon Asset Management S.A. and Bank of Montreal Can. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $91.53.
How big of a company is AbbVie?
AbbVie has a market capitalization of $137.68 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.
What is AbbVie's official website?
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (NYSE ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
